What's on this Page
Second line therapies for glioblastoma
Have any second line therapies been found for glioblastoma?
In 2009, the Food and Drug Administration approved the use of bevacizumab, a monoclonal antibody that binds vascular endothelial growth factor, for monotherapy in recurrent glioblastoma.
